Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection - Test2 - elhamkhani - TriplyDB

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

http://www.wikidata.org/entity/Q27860901

about

Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis Treatment of hepatitis C in children: a systematic review Viral hepatitis and hepatocellular carcinoma HIV and hepatitis C virus infections among hanka injection drug users in central Ukraine: a cross-sectional survey A new insight into hepatitis C vaccine development The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis PEGylation of Interferon-β-1a Hepatitis C: a review for primary care physicians Pathogenesis of hepatitis C during pregnancy and childhood Nitazoxanide for chronic hepatitis C Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C Protease inhibitors in combination with pegylated interferon and ribavirin for adult patients with chronic hepatitis C virus Nitazoxanide for chronic hepatitis C virus infection Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks for patients with chronic hepatitis C virus genotype 1 infection having shown slow antiviral response Pegylated interferon alpha 2a versus pegylated interferon alpha 2b for chronic hepatitis C Ribavirin plus interferon versus interferon for chronic hepatitis C Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C Hepatitis C virus non-structural protein NS5A interacts with FKBP38 and inhibits apoptosis in Huh7 hepatoma cells A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase Antiviral therapy of HCV in the cirrhotic and transplant candidate.Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I Identification of hepatoprotective flavonolignans from silymarin Outcomes of treatment for hepatitis C virus infection by primary care providers Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Antiviral drugs for viruses other than human immunodeficiency virus Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3?Genetic history of hepatitis C virus in East Asia Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial Clinical Profiles of Chronic Hepatitis C in a Major County Medical Center Outpatient Setting in United States.High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study Optimal clinical trial designs for immune-based therapies in persistent viral infections Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells.Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication.Variation in hepatitis C services may lead to inequity of heath-care provision: a survey of the organisation and delivery of services in the United Kingdom Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patients

P2860

Q21132564-687D00F3-B6C2-43EC-87CC-B8B48125D767 Q21136318-4F328D9A-C6DF-4B1F-AED3-66251EBA1E1F Q21245597-AC237724-0922-46CA-8E4E-0198589DC1A7 Q21245627-DF90D131-27C1-4C15-B073-CA8570D0E564 Q21296858-3FDD4634-6EFA-472A-951B-8582D6CC04F4 Q21563395-292A1D1D-B00C-40D2-A94C-B998A0DBFE74 Q22241420-148C160E-F8B1-43C9-B87C-C4466B81BD28 Q22306040-E1642B9C-FE43-4D7B-B6D5-D310CF73F894 Q22809427-12F9F853-55D6-458A-AEF6-E224E6510686 Q24197485-5DA6C22D-8218-45BC-A508-FB64D327142E Q24200189-1CA24A1F-658A-42BE-AAC9-60F8CA78239B Q24200534-C63DA181-FA3D-46B0-99F5-4E7CCFD1702D Q24201588-3E8BCBF4-1051-4D7F-B9D7-A7BBE1010FC2 Q24202464-5EEDA856-6CEE-4646-A915-9D0616BB423E Q24234215-7B414879-EF36-4095-BC28-F6B781DCA8F4 Q24235606-7927B3F9-67C6-4BED-AC9A-371E9A98149E Q24240315-10979E6E-186E-4F9F-875F-9DAF83BB8DC5 Q24240879-CBA2C41D-68F0-4B88-93D4-4877636EC28D Q24241360-44CEE4CF-D67E-41A3-BD13-E27A64A3A937 Q24297145-51368E80-88D8-4247-9939-96FC2542EBA9 Q24301928-38FD8054-ED61-4437-8F1B-19500DA21FA4 Q24314907-BA217A01-629D-45C4-A796-BCF3ECB43CC8 Q24541565-3BDD9A8E-98DE-47AA-A802-527BFA1B0FAB Q24556673-CE89CCA7-8311-4D3F-A168-FEC229759EDA Q24600492-2C6AC235-F024-47DA-B2A2-81DC5A0A7A45 Q24601722-634C575B-FBDD-4CD0-83CE-50C2DA3AA056 Q24624237-9BC8A304-C440-437A-962D-BF416D464E59 Q24632766-CEB9B1EE-74C9-4AD2-A669-61FB62E8F796 Q24635330-CD0EBAA5-1D9D-4B49-A68F-959206FE024D Q24644729-634A6532-0316-415D-B555-A6E0BDBC9862 Q24655361-1C89C678-B7BD-43B5-B09D-46064134922B Q24683611-6F819350-21B5-43EE-B267-0D63CD33771B Q24791398-D899968F-0C8F-41A0-A530-EFBD2F9823BA Q24799492-FB0DF4D7-5BB6-4EE9-9AFD-8F0574144EA0 Q24799820-682CC905-E2EE-4FED-84BF-EBDE7540E631 Q24805127-DFD37B76-4463-4464-928C-62B352C8C7C4 Q24813993-F3E114F1-A3BF-49C5-9E44-929B3F8031EB Q24815995-FC2D6A2E-AC9C-4036-B8FE-EC2659EB6D75 Q25256731-C84DE0B4-53BD-45A0-BD7A-C37ED8685254 Q25257004-58AE0150-E0DB-4356-A8A9-185673824327

P2860

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

http://www.wikidata.org/entity/Q27860901

description

2002 nî lūn-bûn

@nan

2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

@ast

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

@en

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

@nl

type

label

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

@ast

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

@en

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

@nl

prefLabel

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

@ast

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

@en

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

@nl

P1433

Q27860901-4C99945E-21DA-4DBE-8282-4367376B996B

P1476

Q27860901-B579610B-A12D-477C-B67A-F694103C2C2B

P2093

Q27860901-257A2FBF-1343-41AB-90F0-5EDC025846D1

Q27860901-5917F327-013C-4618-959C-542F404CEFF5

Q27860901-6FE12A8E-52BD-469E-ACA1-8DA96A00AE03

Q27860901-92E35E69-FB31-486D-A570-7C758385DF30

Q27860901-987F1614-53CB-4744-BD0E-0D5EC8B4CA46

Q27860901-A548FF1E-9146-4D58-B886-E465221E031F

Q27860901-C4F938EC-B3FC-4C8D-B753-3BAE2D87B975

Q27860901-ECB6CD08-6C09-4DAF-9EEB-356A05E2D84E

Q27860901-EF42656E-79C0-4F1C-9244-79D9EE597F66

Q27860901-F772521A-1AB0-4804-96CE-33A91C8BC81B

P304

Q27860901-DC81CD3C-4C0D-4637-8715-3BE0393B47EA

P31

Q27860901-D12BF191-C258-4CAF-BAD4-4951EE4C924D

P3181

Q27860901-F9716495-2459-464A-BACE-90835C8C9A86

P356

Q27860901-8CCE084F-0033-4073-9D86-BE8C30CB972C

P407

Q27860901-D1BE79EF-6AA5-436F-B767-CC4389EDA36B

P433

Q27860901-ECB8A3DA-1301-4F28-896F-9783FD270868

P478

Q27860901-7F2DD6F9-86F5-436C-B9CB-4026C4F11CE2

P50

Q27860901-1E85189E-5AF9-4124-8F2D-61DE33ABDA83

Q27860901-3A85AC89-3667-4081-A35F-08B853E6DA17

Q27860901-7E66B4F0-FA8A-460E-BA46-CD94F64BA4B5

Q27860901-8C1A7AEC-FB50-4579-AE3B-4DF282F868F1

P577

Q27860901-E50F80DD-E7C2-4412-A6F3-BFD1984A6F4B

P698

Q27860901-CD911FA9-72E1-4820-97E7-9D1441969405

P921

Q27860901-31f72909-4d82-a8b0-a4b5-cb3f0d55d262

P3181

P356

P1433

The New England Journal of Medicine

P1476

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

@en

P2093

Amy Lin

http://www.w3.org/2001/XMLSchema#string

Coleman Smith

http://www.w3.org/2001/XMLSchema#string

Daniel Dhumeaux

http://www.w3.org/2001/XMLSchema#string

Fernando L Gonçales

http://www.w3.org/2001/XMLSchema#string

George Marinos

http://www.w3.org/2001/XMLSchema#string

Jian Yu

http://www.w3.org/2001/XMLSchema#string

Joseph Hoffman

http://www.w3.org/2001/XMLSchema#string

Michael W Fried

http://www.w3.org/2001/XMLSchema#string

Mitchell L Shiffman

http://www.w3.org/2001/XMLSchema#string

Moises Diago

http://www.w3.org/2001/XMLSchema#string

P304

975-82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

408788

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA020047

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

347

http://www.w3.org/2001/XMLSchema#string

P50

Dieter Häussinger

Giampiero Carosi

K. Rajender Reddy

P577

2002-09-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12324553

http://www.w3.org/2001/XMLSchema#string

P921

Hepatitis C virus